{
    "nctId": "NCT03505164",
    "briefTitle": "The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor",
    "officialTitle": "The Role of suPAR in Doxorubicin Induced Cardiomyopathy in Breast Cancer Patients: Causative vs. Predictor",
    "overallStatus": "COMPLETED",
    "conditions": "Doxorubicin Adverse Reaction, Cardiomyopathies, Secondary, Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 42,
    "primaryOutcomeMeasure": "Causality relationship between the suPAR blood level and doxorubicin-induced cardiomyopathy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 - 64 years\n* Undergoing chemotherapy in the Rush cancer center with a plan for doxorubicin (Adriamycin\u00ae) chemotherapy.\n\nExclusion Criteria:\n\n* Patients with metastatic breast cancer - complicated chemotherapy regimens, higher mortality risk\n* HER2 (human epidermal growth factor receptor 2) positive breast cancer patients planned for trastuzumab therapy\n* Patients with baseline cardiomyopathy (reduced LVEF: less than 50%)\n* Patients with prior cardiovascular history of myocardial infarction (MI), angina, Congestive Heart Disease (CHD) death, coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI) including percutaneous transluminal coronary angioplasty (PTCA) and end-stage renal disease (ESRD), atrial fibrillation prior to cancer diagnosis\n* Atrial fibrillation noted on baseline ECG",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}